A monoclonal antibody to human B lymphoblastoid cells activates human and murine T lymphocytes

Hardy, Britta; Dotan, Dalia; Novogrodsky, Abraham

doi:10.1016/0008-8749(89)90354-7

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A monoclonal antibody prepared against cell membranes of Daudi cells was investigated. This antibody, termed BAT, was found to induce T cell proliferation and increase cytotolytic activity in human peripheral blood cells [34]. Administration of BAT monoclonal antibody to experimental tumor bearing mice demonstrated striking anti tumor activities in a wide range of both murine and human tumors [35][36][37][38][39].…”

Section: The Use Of Antibodies In Cancer Therapymentioning

confidence: 99%

New era in cancer immunotherapy: Twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors

Hardy¹,

Raiter²

2013

ABB

Self Cite

View full text Add to dashboard Cite

The better understanding of the mechanism in which the immune system responds to the developing cancer provided the outcome in a new era in cancer immunotherapy. The tumor suppressive effect on the immune system is caused by negative T cell receptor signaling that abrogate immunity against the cancer cells. Novel monoclonal antibodies that target co-inhibitory receptors on T cells block the tumor induced inhibition of the immune system and enable the immune system to eradicate the tumors. The development of such antibodies started twenty years ago by the preparation of a monoclonal antibody termed BAT. A single administration of the antibody to tumor bearing mice resulted in striking anti tumor activity that was mediated by the lymphocytes. These studies provided a basis for the new era of cancer immunotherapy. The present review summarizes twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors.

show abstract

Section: The Use Of Antibodies In Cancer Therapymentioning

confidence: 99%

New era in cancer immunotherapy: Twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors

Hardy¹,

Raiter²

2013

ABB

Self Cite

View full text Add to dashboard Cite

show abstract

“…BAT is a murine mAb developed against a membrane preparation of a Burkitt lymphoma cell line (Daudi). The mAbs were selected by binding to Daudi cells and by their ability to induce human PBMC proliferation (11,13). The BAT mAb is produced from either in vitro hybridoma cultures grown in RPMI-1640 medium supplemented with 10% FCS or from mice ascites, followed by purification on a protein G Sepharose column (Pharmacia, Uppsala, Sweden).…”

Section: Bat Antibodymentioning

confidence: 99%

BAT mAb induces lymphopoiesis in nude mice

Hardy¹,

Niv²,

Fadaeev³

et al. 2005

International Immunology

Self Cite

View full text Add to dashboard Cite

The athymic nude mouse provides a powerful tool in the study of human tumors, as it enables growth of human tumors due to deficiencies in T cell functions. However, deficiencies in T cell functions might limit research on efficacy of immune modulators in cancer immunotherapy. BAT mAb mediates its anti-cancer activity through modulation of the immune system that involves both NK and T cells. We analyzed lymphocyte populations in blood 5 and 14 days following the injection of BAT antibody alone or following engraftment of human colon carcinoma cells. Our results demonstrate that BAT injection induced lymphopoiesis in the nude mouse. Percentage of CD3 cells increased up to 24%, CD4 cells up to 20% but no increase was found in CD8 T cells in BAT-injected nude mice. Injection of BAT 12 days post-tumor engraftment propagated CD3, CD4 and CD8 cells seen in the blood 5 days later but not seen in the blood 14 days post-BAT injection. It is possible that this decrease is associated with migration of the lymphocytes from the blood to the tumor sites in the livers. The percentage of CD56-positive NK cells increased (up to 18%) by BAT administration alone or post-tumor injection. The presence of tumors alone did not induce lymphopoiesis in the nude mice. Propagation and lymphopoiesis by BAT mAb might have future clinical implications.

show abstract